Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 215

Sort by

Sort Order Select

Journal Articles

EPCR deficiency or function-blocking antibody protects against joint bleeding–induced pathology in hemophilia mice

Jhansi Magisetty, Usha R. Pendurthi, Charles T. Esmon, L. Vijaya Mohan Rao

Blood (2020) 135 (25): 2211–2223.

https://doi.org/10.1182/blood.2019003824

Published: 2020

Includes: Supplemental data

Journal Articles

Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial

Gavin Cull, MB, BS, FRACP, FRCPA, David Simpson, MBChB, FRACP, FRCPA, Stephen Opat, Jan A. Burger, MD PhD, Judith Trotman, MBChB, FRACP, FRCPA, Paula Marlton, MBBS (Hons), FRACP, FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA, Javier Munoz, MD MS, FACP, John F. Seymour, MBBS, PhD FRACP, Andrew W. Roberts, MBBS, PhD, Ken Wu, PhD, Siminder Atwal, PhD, William Novotny, MD, Jane Huang, MD, Constantine S. Tam, MBBS, MD

Blood (2019) 134 (Supplement_1): 500.

https://doi.org/10.1182/blood-2019-125483

Published: 2019

Journal Articles

Non-Canonical MYD88/TIRAP-Dependent Anti-Inflammatory Function of Pro-Coagulant Factor VIII

Sandra Mignot, Sandrine Delignat, PhD, Sebastien Lacroix-demaze, PhD, Christine Bole-Feysot, PhD, Sherine Tei, Ananthy Kiddinan, Olivier Hermine, MD PhD, Laurent Frenzel, MD PhD

Blood (2019) 134 (Supplement_1): 3638.

https://doi.org/10.1182/blood-2019-127504

Published: 2019

Journal Articles

Real-World Clinical Management of Patients with Hemophilia and Inhibitors: Effectiveness and Safety of aPCC in Patients with >18 Months' Follow-up in the FEIBA Global Outcome Study (FEIBA GO)

Jerzy Windyga, Pal A Holme, C. Hermans, Ana R Cid, Nirjhar Chatterjee, Hongyu Jiang, Viridiana Cano-Garcia, Carmen Escuriola

Blood (2019) 134 (Supplement_1): 2418.

https://doi.org/10.1182/blood-2019-124324

Published: 2019

Journal Articles

Innate Immune Mechanism of Hemarthrosis in Hemophilia-a Mice

Tomasz W. Kaminski, PharmD, Egemen Tutuncuoglu, MSc, Margaret V. Ragni, MD MPH, Mark T Gladwin, MD, Prithu Sundd, PhD

Blood (2019) 134 (Supplement_1): 1043.

https://doi.org/10.1182/blood-2019-130471

Published: 2019

Journal Articles

Associated Co-Morbidities, Healthcare Utilization, and Mortality in Hospitalized Children and Adults with Hemophilia in the United States: Updated Nationally Representative Estimates and a Comparative Analysis

Ashwin Gupta, Abdul Hannan, MD, Ruby Maini, MD, Stephanie Bitner, Pharm D, Schuyler Stone, MD, Manjari Regmi, MD, Aaron Tobian, MD PhD, Cassandra D Josephson, MD, Lakshmanan Krishnamurti, MD, Clifford M. Takemoto, MD, Ruchika Goel, MD MPH

Blood (2019) 134 (Supplement_1): 4711.

https://doi.org/10.1182/blood-2019-123161

Published: 2019

Journal Articles

Mechanisms of Iron Clearance from the Joint in FVIII-Deficient Mice after Induced Hemarthrosis

Esther J Cooke, PhD, Chanond A Nasamran, Kathleen M Fisch, Annette von Drygalski, MD PharmD

Blood (2019) 134 (Supplement_1): 157.

https://doi.org/10.1182/blood-2019-131576

Published: 2019

Journal Articles

Prevention of Bleeding-Induced Vascular Abnormalities in the Hemophilic Mouse Joint By Increasing TAFI Levels or Inhibiting uPA Activity

Tine Wyseure, PhD, Niels Behrendt, Annette von Drygalski, MD PharmD, Laurent O Mosnier

Blood (2019) 134 (Supplement_1): 158.

https://doi.org/10.1182/blood-2019-128723

Published: 2019

Journal Articles

EPCR Deficiency Prevents Development of Hemophilic Arthropathy

Jhansi Magisetty, PhD MSc, Usha Pendurthi, PhD, Charles T. Esmon, PhD, L. Vijaya Mohan Rao, PhD

Blood (2019) 134 (Supplement_1): 159.

https://doi.org/10.1182/blood-2019-124972

Published: 2019

Journal Articles

"a Needle in a Haystack". Let´s Talk about Acquired Hemophilia in Pediatrics

German Alejandro Detarsio, Sr., BSc, Mariana Raviola, Mauro Davoli, MD, Maria Fabiana Garcia

Blood (2019) 134 (Supplement_1): 4936.

https://doi.org/10.1182/blood-2019-125977

Published: 2019

Journal Articles

Immune Tolerance Induction (ITI) with a Plasma-Derived Factor VIII for Patients with Hemophilia a and Inhibitors: A Retrospective Study

Miguel A. Escobar, MD, Linda Shaffer, Mark Holguin, MD, Timothy McCavit, MD, Sandeep K. Rajan, MD, Novinyo Amega, MD

Blood (2019) 134 (Supplement_1): 4923.

https://doi.org/10.1182/blood-2019-122949

Published: 2019

Journal Articles

Acquired Hemophilia and Plasma Cell Neoplasms, a Rare Association

Katarzyna Aleksandra Jalowiec, Martin Andres, Behrouz Mansouri Taleghani, Anne Angelillo-Scherrer, MD PhD, Alicia Rovo, Johanna A. Kremer Hovinga, MD Prof

Blood (2019) 134 (Supplement_1): 4930.

https://doi.org/10.1182/blood-2019-128048

Published: 2019

Journal Articles

Prospective Controlled Monitoring of Hemlibra Prophylaxis Initiation in a Large Cohort of Hemophilia a Patients- Real World Data

Assaf Arie Barg, Tami Livnat, PhD, Tami Brutman-Barazani, Nurit Rosenberg, Ivan Budnik, MD PhD, Gili Kenet

Blood (2019) 134 (Supplement_1): 2397.

https://doi.org/10.1182/blood-2019-122010

Published: 2019

Journal Articles

Benefits of Ehl Factor VIII Replacement Therapy in Hemophilia: Observations on Coverage, Physical Activity and Phisiotherapy

Felipe Querol, MD PhD, Sofía Pérez-Alenda, PhD, Juan Eduardo Megias, Juan José Carrasco, MSc, Marta Aguilar, PhD, Saturnino Haya, MD, Ana R Cid, Santiago Bonanad Boix, MD

Blood (2019) 134 (Supplement_1): 2455.

https://doi.org/10.1182/blood-2019-125651

Published: 2019

Journal Articles

Quantitative Measurements of Hemophilic Joint Tissues By Point-of-Care Musculoskeletal Ultrasound Are Associated with Clinical and Functional Joint Outcome Parameters

Akram Mesleh Shayeb, MD, Richard Barnes, PhD MPH, Cris Hanacek, BS, Andres Flores, MS, ATC, CES, Rebecca Kruse-Jarres, MDMPH, Bruno Steiner, PT, DPT, LMT, RMSK, Doris Quon, MD PhD, Cindy Bailey, DPT, OCS, SCS, ATC, Annette von Drygalski, MD PharmD

Blood (2019) 134 (Supplement_1): 905.

https://doi.org/10.1182/blood-2019-129690

Published: 2019

Journal Articles

Treatment of rare factor deficiencies other than hemophilia

Marzia Menegatti, Flora Peyvandi

Blood (2019) 133 (5): 415–424.

https://doi.org/10.1182/blood-2018-06-820738

Published: 2019

Journal Articles

Systemic Vascular Basement Membrane Markers Linked to Synovial Vascular Remodeling Are Bio-Markers of Hemarthrosis in Patients with Hemophilia

Srila Gopal, MD, Esther J Cooke, Jenny Y Zhou, Ilana Levin, Pamela Emery, Tina Manon- Jensen, Morten Karsdal, Annette von Drygalski, MD

Blood (2018) 132 (Supplement 1): 380.

https://doi.org/10.1182/blood-2018-99-112725

Published: 2018

Journal Articles

Systemic Transcriptional Responses to Hemarthrosis and FVIII Replacement in FVIII-Deficient Mice

Esther J Cooke, Srila Gopal, John Shimashita, Chanond A Nasamran, Kathleen M Fisch, Laurent O Mosnier, Annette von Drygalski

Blood (2018) 132 (Supplement 1): 381.

https://doi.org/10.1182/blood-2018-99-120092

Published: 2018

Journal Articles

A Practical, One Clinic Visit, Population Pharmacokinetic (PK) Protocol for Generation of PK Profiles in Subjects with Severe Hemophilia a

Victor S. Blanchette, FRCP, Laura Tiseo, BSc, CCRP, David Lillicrap, MD, Shannon Jackson, MD FRCPC, Massimo Morfini, MD, Vanessa Bouskill, MN, Manuel Carcao, Margaret L. Rand, PhD, Derek Stephens, MSc, Liane Khoo, MD, Ester Zapotocka, MD, Vladimir Komrska, MD, Jan Blatny, MD PhD

Blood (2018) 132 (Supplement 1): 2480.

https://doi.org/10.1182/blood-2018-99-111024

Published: 2018

Journal Articles

Hemostatic Effect of the Combination of Factor VIII Concentrate with Tranexamic Acid (TXA) in the Prophylactic Setting in Severe Hemophilia a

Maissaa Janbain, MD, Nathalie Enjolras, PhD, Jean-Claude Bordet, Radu Bolbos, Cindy A. Leissinger, MD, Yesim Dargaud, MD PhD

Blood (2018) 132 (Supplement 1): 2490.

https://doi.org/10.1182/blood-2018-99-119407

Published: 2018

NARROW

EPCR deficiency or function-blocking antibody protects against joint bleeding–induced pathology in hemophilia mice

Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial

Non-Canonical MYD88/TIRAP-Dependent Anti-Inflammatory Function of Pro-Coagulant Factor VIII

Real-World Clinical Management of Patients with Hemophilia and Inhibitors: Effectiveness and Safety of aPCC in Patients with >18 Months' Follow-up in the FEIBA Global Outcome Study (FEIBA GO)

Innate Immune Mechanism of Hemarthrosis in Hemophilia-a Mice

Associated Co-Morbidities, Healthcare Utilization, and Mortality in Hospitalized Children and Adults with Hemophilia in the United States: Updated Nationally Representative Estimates and a Comparative Analysis

Mechanisms of Iron Clearance from the Joint in FVIII-Deficient Mice after Induced Hemarthrosis

Prevention of Bleeding-Induced Vascular Abnormalities in the Hemophilic Mouse Joint By Increasing TAFI Levels or Inhibiting uPA Activity

EPCR Deficiency Prevents Development of Hemophilic Arthropathy

"a Needle in a Haystack". Let´s Talk about Acquired Hemophilia in Pediatrics

Immune Tolerance Induction (ITI) with a Plasma-Derived Factor VIII for Patients with Hemophilia a and Inhibitors: A Retrospective Study

Acquired Hemophilia and Plasma Cell Neoplasms, a Rare Association

Prospective Controlled Monitoring of Hemlibra Prophylaxis Initiation in a Large Cohort of Hemophilia a Patients- Real World Data

Benefits of Ehl Factor VIII Replacement Therapy in Hemophilia: Observations on Coverage, Physical Activity and Phisiotherapy

Quantitative Measurements of Hemophilic Joint Tissues By Point-of-Care Musculoskeletal Ultrasound Are Associated with Clinical and Functional Joint Outcome Parameters

Treatment of rare factor deficiencies other than hemophilia

Systemic Vascular Basement Membrane Markers Linked to Synovial Vascular Remodeling Are Bio-Markers of Hemarthrosis in Patients with Hemophilia

Systemic Transcriptional Responses to Hemarthrosis and FVIII Replacement in FVIII-Deficient Mice

A Practical, One Clinic Visit, Population Pharmacokinetic (PK) Protocol for Generation of PK Profiles in Subjects with Severe Hemophilia a

Hemostatic Effect of the Combination of Factor VIII Concentrate with Tranexamic Acid (TXA) in the Prophylactic Setting in Severe Hemophilia a

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only